Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
暂无分享,去创建一个
J. Friedberg | J. Liesveld | C. Abboud | M. Becker | A. Walker | R. Komrokji | J. Ifthikharuddin | D. Mulford | G. Phillips | J. Oliva | P. Messina